quinazolines has been researched along with Dyspnea in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acquaviva, G; Brand, T; Brandes, AA; Cavallo, G; de Biase, D; Degli Esposti, R; Di Battista, M; Genestreti, G; Pession, A; Tallini, G; Visani, M | 1 |
| Chang, HT; Chen, CA; Chen, CY; Chen, YJ; Chong, NS; Hsieh, CH; Hsieh, YP; Lin, SC; Lin, SL; Shueng, PW; Wang, LY | 1 |
| Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Kuo, LC; Lai, YC; Liu, YC; Yu, CJ; Yuan, MK | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Choe, JK; Cogswell, J; Kasimis, B; Nagaria, NC | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Soda, H | 1 |
| Gatzemeier, U; Reck, M | 1 |
| Ceribelli, A; Cognetti, F; Gelibter, A; Milella, M; Moscetti, L; Pollera, CF; Sperduti, I | 1 |
| Ayoub, J; Bezjak, A; Chan, RT; Clark, G; Cyjon, A; de Albuquerque Ribeiro, R; Fenton, D; Gerogianni, A; Laberge, F; Lago, S; Noble, J; Reck, M; Seymour, L; Shepherd, FA; Trajkovic, A; Tu, D; von Pawel, J; Zukin, M | 1 |
| Awan, NA; Evenson, MK; Mason, DT; Needham, KE | 1 |
| Bertel, O | 1 |
| De Mey, J; Meysman, M; Neyns, B; Schallier, D | 1 |
| Awan, NA; DeMaria, AN; Mason, DT; Maxwell, KS; Miller, RR; Neumann, A | 1 |
1 review(s) available for quinazolines and Dyspnea
| Article | Year |
|---|---|
Management of refractory congestive heart failure with prazosin.
Topics: Animals; Drug Evaluation; Drug Tolerance; Dyspnea; Echocardiography; Fatigue; Heart Failure; Hemodynamics; Humans; Hyperaldosteronism; Physical Exertion; Prazosin; Quinazolines; Receptors, Adrenergic, alpha; Time Factors; Vasodilator Agents | 1981 |
5 trial(s) available for quinazolines and Dyspnea
| Article | Year |
|---|---|
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gefitinib; Health Status; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Function Tests; Retrospective Studies; Sex Factors; Survival Analysis; Treatment Outcome | 2005 |
Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Constipation; Disease Progression; Dyspnea; Fatigue; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2005 |
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pain; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2006 |
8 other study(ies) available for quinazolines and Dyspnea
| Article | Year |
|---|---|
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
Topics: Adenocarcinoma; Aged; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Dyspnea; ErbB Receptors; Exons; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines | 2017 |
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dyspnea; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Female; Gefitinib; Hospital Mortality; Humans; Hypoxia; Incidence; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Taiwan | 2013 |
Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis; Quinazolines | 2005 |
Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Dyspnea; Female; Gefitinib; Humans; Lung Neoplasms; Mucins; Quinazolines | 2005 |
Long-term therapy with prazosin in severe chronic congestive heart failure.
Topics: Blood Pressure; Capillary Resistance; Dyspnea; Heart Failure; Heart Rate; Humans; Prazosin; Quinazolines; Stroke Volume | 1980 |
Raltitrexed-related pulmonary toxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dyspnea; Female; Humans; Lung Diseases; Quinazolines; Radiography, Thoracic; Thiophenes | 2000 |
Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodyn
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Blood Pressure; Cardiac Output; Chronic Disease; Coronary Disease; Drug Evaluation; Dyspnea; Echocardiography; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prazosin; Quinazolines; Vascular Resistance; Vasodilator Agents | 1977 |